NASH
MCID: NNL002
MIFTS: 50

Nonalcoholic Steatohepatitis (NASH) malady

Categories: Rare diseases, Gastrointestinal diseases, Liver diseases

Aliases & Classifications for Nonalcoholic Steatohepatitis

Aliases & Descriptions for Nonalcoholic Steatohepatitis:

Name: Nonalcoholic Steatohepatitis 50 25 69
Non-Alcoholic Fatty Liver Disease 50 25 69
Fatty Liver 25 52 69
Non-Alcoholic Steatohepatitis 50 25
Nash 50 25
Nonalcoholic Fatty Liver Disease 25
Fatty Degeneration 69
Steatohepatitis 69
Steatosis 25
Nafld 25

Classifications:



External Ids:

ICD10 33 K76.0

Summaries for Nonalcoholic Steatohepatitis

NIH Rare Diseases : 50 nonalcoholic steatohepatitis, or nash, is a common, often “silent” liver disease. it resembles alcoholic liver disease, but occurs in people who drink little or no alcohol. the major feature in nash is fat in the liver, along with inflammation and damage. most people with nash feel well and are not aware that they have a liver problem. nevertheless, nash can be severe and can lead to cirrhosis, in which the liver is permanently damaged and scarred and no longer able to work properly. nash most often occurs in people who are middle aged and overweight or obese. affected individuals may also have elevated levels of blood lipids (such as cholesterol and triglycerides) and many have diabetes or prediabetes. treatment is centered around working towards a healthy lifestyle, including weight reduction, dietary modification, increased activity and avoidance of alcohol and unnecessary medications. the underlying cause of nash remains unclear. last updated: 2/24/2012

MalaCards based summary : Nonalcoholic Steatohepatitis, also known as non-alcoholic fatty liver disease, is related to visceral steatosis and fatty liver disease, nonalcoholic 1. An important gene associated with Nonalcoholic Steatohepatitis is KRT18 (Keratin 18), and among its related pathways/superpathways are Common Cytokine Receptor Gamma-Chain Family Signaling Pathways and Circadian rythm related genes. The drugs Rosiglitazone and Ezetimibe have been mentioned in the context of this disorder. Affiliated tissues include liver, kidney and testes, and related phenotypes are growth/size/body region and homeostasis/metabolism

Genetics Home Reference : 25 Non-alcoholic fatty liver disease (NAFLD) is a buildup of excessive fat in the liver that can lead to liver damage resembling the damage caused by alcohol abuse, but that occurs in people who do not drink heavily. The liver is a part of the digestive system that helps break down food, store energy, and remove waste products, including toxins. The liver normally contains some fat; an individual is considered to have a fatty liver (hepatic steatosis) if the liver contains more than 5 to 10 percent fat.

Wikipedia : 71 Non-alcoholic fatty liver disease (NAFLD) is one of the types of fatty liver which occurs when fat is... more...

Related Diseases for Nonalcoholic Steatohepatitis

Diseases related to Nonalcoholic Steatohepatitis via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 104)
id Related Disease Score Top Affiliating Genes
1 visceral steatosis 12.0
2 fatty liver disease, nonalcoholic 1 11.8
3 lipoatrophy with diabetes, leukomelanodermic papules, liver steatosis, and hypertrophic cardiomyopathy 11.8
4 lipoatrophy with diabetes, hepatic steatosis, cardiomyopathy, and leukomelanodermic papules 11.8
5 fatty liver disease 11.6
6 hepatitis 10.7
7 liver disease 10.7
8 obesity 10.6
9 hepatocellular carcinoma 10.4
10 hepatitis c 10.4
11 gastric neuroendocrine tumor type 1 10.3 GPT SLC17A5
12 radiation induced cancer 10.2 GPT SLC17A5
13 emery-dreifuss muscular dystrophy 3, ar 10.2 INS LEP
14 hepatitis c virus 10.2
15 hypersensitivity syndrome, carbamazepine-induced 10.2 HFE INS
16 female infertility of uterine origin 10.2 GPT SLC17A5
17 rosacea 10.2 GPT INS SLC17A5
18 ebstein anomaly 10.2 SLC17A5 SLC25A13
19 leg dermatosis 10.2 ADIPOQ INS LEP
20 hyperlipoproteinemia type iv 10.2 ADIPOQ INS LEP
21 alcoholic hepatitis 10.2
22 neurogenic arthropathy 10.2 ADIPOQ INS LEP
23 limb ischemia 10.2 ADIPOQ INS LEP
24 diabetic encephalopathy 10.1 ADIPOQ INS LEP
25 tmem231-related joubert syndrome 10.1 HFE INS
26 brain ependymoma 10.1 INS SLC25A13
27 iida kannari syndrome 10.1 ADIPOQ INS PPARA
28 brain stem glioma 10.1 ADIPOQ INS LEP
29 posterior uveal melanoma 10.1 ADIPOQ HFE INS
30 autosomal recessive congenital ichthyosis 10.1 INS LEP PPARA
31 acrocephalopolydactyly 10.1 ADIPOQ LEP RETN
32 malignant perineurioma 10.1 ADIPOQ LEP RETN
33 nystagmus, congenital motor, autosomal recessive 10.1 ADIPOQ LEP
34 mucinoses 10.1 ADIPOQ LEP RETN
35 paranasal sinus sarcoma 10.1 GPT SLC17A5 SLC25A13
36 congenital hypoplastic anemia 10.1 GPT SLC17A5 SLC25A13
37 cortical blindness mental retardation polydactyly 10.1 ADIPOQ LEP RETN
38 myelophthisic anemia 10.1 ADIPOQ INS PPARA
39 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 10.0 ADIPOQ LEP RETN
40 amelogenesis imperfecta 10.0 CYP2E1 GPT SLC17A5
41 morbid obesity 10.0
42 pancreatitis 10.0
43 polycystic ovary syndrome 10.0
44 atherosclerosis 10.0
45 alopecia 10.0 CYP2E1 GPT SLC17A5
46 noninfectious dermatoses of eyelid 10.0 GPT HFE KRT18 SLC17A5
47 mucopolysaccharidosis iii 10.0 ADIPOQ INS LEP RETN
48 thymus clear cell carcinoma 10.0 ADIPOQ INS LEP RETN
49 antidepressant type abuse 10.0 ADIPOQ INS LEP RETN
50 blind loop syndrome 10.0 ADIPOQ INS LEP RETN

Graphical network of the top 20 diseases related to Nonalcoholic Steatohepatitis:



Diseases related to Nonalcoholic Steatohepatitis

Symptoms & Phenotypes for Nonalcoholic Steatohepatitis

MGI Mouse Phenotypes related to Nonalcoholic Steatohepatitis:

44
id Description MGI Source Accession Score Top Affiliating Genes
1 growth/size/body region MP:0005378 9.96 ADIPOQ HFE INS KRT18 LEP MTTP
2 homeostasis/metabolism MP:0005376 9.9 ADIPOQ CYP2E1 HFE INS LEP MTTP
3 adipose tissue MP:0005375 9.8 ADIPOQ INS LEP PPARA RETN SQSTM1
4 liver/biliary system MP:0005370 9.7 ADIPOQ CYP2E1 HFE INS KRT18 LEP
5 mortality/aging MP:0010768 9.36 HFE INS KRT18 LEP MTTP PPARA

Drugs & Therapeutics for Nonalcoholic Steatohepatitis

Drugs for Nonalcoholic Steatohepatitis (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 491)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Rosiglitazone Approved, Investigational Phase 4,Phase 2,Phase 1 122320-73-4 77999
2
Ezetimibe Approved Phase 4,Phase 2 163222-33-1 150311
3
Pioglitazone Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 111025-46-8 4829
4
Simvastatin Approved Phase 4 79902-63-9 54454
5
Zinc Approved Phase 4,Phase 2 7440-66-6 32051 23994
6
Rifampin Approved Phase 4,Phase 2,Phase 3,Phase 1 13292-46-1 5458213 5381226
7
Epinephrine Approved, Vet_approved Phase 4,Phase 2 51-43-4 5816
8
Iron Approved Phase 4,Phase 3,Phase 1,Phase 2 7439-89-6 23925
9
Metformin Approved Phase 4,Phase 2,Phase 3,Phase 1 657-24-9 14219 4091
10
Losartan Approved Phase 4,Phase 3,Phase 2 114798-26-4 3961
11
Valsartan Approved, Investigational Phase 4,Phase 3 137862-53-4 60846
12
Hydrochlorothiazide Approved, Vet_approved Phase 4,Phase 3 58-93-5 3639
13
Amlodipine Approved Phase 4 88150-42-9 2162
14
Glycerol Approved, Experimental Phase 4 56-81-5 753
15
Ribavirin Approved Phase 4,Phase 3 36791-04-5 37542
16
Hydrocortisone Approved, Vet_approved Phase 4,Phase 2 50-23-7 5754 657311
17
Isoniazid Approved Phase 4,Phase 2,Phase 3,Phase 1 54-85-3 3767
18
Pyrazinamide Approved Phase 4,Phase 2,Phase 3,Phase 1 98-96-4 1046
19
Cortisone acetate Approved Phase 4 1950-04-4, 50-04-4 5745
20
Entecavir Approved, Investigational Phase 4 142217-69-4 153941
21
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
22
Ethanol Approved Phase 4,Phase 3,Phase 2 64-17-5 702
23
Heparin Approved, Investigational Phase 4 9005-49-6 772 46507594
24
Tamoxifen Approved Phase 4 10540-29-1 2733526
25
Zidovudine Approved Phase 4 30516-87-1 35370
26
Tenofovir Approved, Investigational Phase 4 147127-20-6 464205
27
Lamivudine Approved, Investigational Phase 4 134678-17-4 60825
28
Gliclazide Approved Phase 4 21187-98-4 3475
29
Glipizide Approved Phase 4 29094-61-9 3478
30
Sorafenib Approved, Investigational Phase 4 284461-73-0 216239 406563
31
Orlistat Approved, Investigational Phase 4,Phase 2 96829-58-2 3034010
32
Stavudine Approved, Investigational Phase 4 3056-17-5 18283
33
Abacavir Approved, Investigational Phase 4 136470-78-5 65140 441300
34
Selenium Approved, Vet_approved Phase 4 7782-49-2
35
Miconazole Approved, Investigational, Vet_approved Phase 4,Early Phase 1 22916-47-8 4189
36
Anastrozole Approved, Investigational Phase 4 120511-73-1 2187
37
Exenatide Approved, Investigational Phase 4,Phase 2,Phase 3 141758-74-9 15991534
38
Emtricitabine Approved, Investigational Phase 4 143491-57-0 60877
39
Liraglutide Approved Phase 4,Phase 3,Phase 2 204656-20-2
40
Menthol Approved Phase 4 2216-51-5 16666
41
Empagliflozin Approved Phase 4,Phase 3 864070-44-0
42
Insulin Aspart Approved Phase 4 116094-23-6 16132418
43
Insulin Glargine Approved Phase 4,Phase 2 160337-95-1
44
Insulin Detemir Approved Phase 4 169148-63-4 5311023
45
Rifaximin Approved, Investigational Phase 4 80621-81-4 6436173
46
Toremifene Approved, Investigational Phase 4 89778-26-7 3005573
47
Glimepiride Approved Phase 4 93479-97-1 3476
48
Perindopril Approved Phase 4 107133-36-8, 82834-16-0 107807
49
Telmisartan Approved, Investigational Phase 4 144701-48-4 65999
50
Saxagliptin Approved Phase 4 361442-04-8 11243969

Interventional clinical trials:

(show top 50) (show all 914)
id Name Status NCT ID Phase
1 Placebo Controlled Study Using Lovaza as Treatment for Non-Alcoholic Fatty Liver Disease Unknown status NCT00941642 Phase 4
2 The Effect Of Dual Treatment With L-Carnitine And Magnesium On Fatty Liver Unknown status NCT01956825 Phase 4
3 Influence of Hepatic Steatosis on the Therapeutic Effect of Entecavir in Chronic Hepatitis B Patients Unknown status NCT01148576 Phase 4
4 Lifestyle Versus Ezetimibe Plus Lifestyle in Patients With Non-alcoholic Steatohepatitis Unknown status NCT01950884 Phase 4
5 Losartan and Simvastatin in Hypertensive Obeses With Liver Steatosis Unknown status NCT00669435 Phase 4
6 Trial Comparing Metformin Versus Placebo in Non Alcoholic Steatohepatitis (NASH) Patients Receiving Bariatric Surgery for Obesity Unknown status NCT00134303 Phase 4
7 Effect of Dietary and Life Style Modification on Post Liver Transplant Obesity Unknown status NCT00878592 Phase 4
8 Regression of Fatty Heart by Valsartan Therapy Unknown status NCT00745953 Phase 4
9 Dual RElease Hydrocortisone Versus conventionAl Glucocorticoid replaceMent Therapy in Hypocortisolism (DREAM) Unknown status NCT02277587 Phase 4
10 Lovaza Mechanisms of Action Unknown status NCT01301794 Phase 4
11 Parenteral Fish Oil in Major Laparoscopic Abdominal Surgery Unknown status NCT01819961 Phase 4
12 Fat, Inflammation and Insulin Resistance Unknown status NCT01054989 Phase 4
13 Effects of Parenteral Nutrition With Different Lipid Emulsions in Preterm Infants Unknown status NCT01683162 Phase 4
14 Reintroduction Regimens After Hepatitis During Anti-tuberculosis Treatment Unknown status NCT01395654 Phase 4
15 Adding Exenatide to Insulin Therapy for Patients With Type 2 Diabetes and Non-Alcoholic Fatty Liver Disease Completed NCT01006889 Phase 4
16 Effects of Siliphos-Selenium-Methionine-Alpha Lipoic Acid in Patients With Fatty Liver and Non-alcoholic Steatohepatitis Completed NCT01650181 Phase 4
17 Effects of Exenatide (Byetta®) on Liver Function in Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT01208649 Phase 4
18 Study for the Treatment of Significant Steatosis With Xenical Followed by Treatment of Hepatitis C With Pegasys/Copegus Completed NCT00207311 Phase 4
19 Prevalence of Non-alcoholic Fatty Liver Disease (NAFLD) in Hispanics With Diabetes Mellitus Type 2 (T2DM) and Role of Treatment Completed NCT01002547 Phase 4
20 University of Texas H.S.C. San Antonio Pioglitazone in Non-Alcoholic Steatohepatitis Trial (UTHSCSA NASH Trial) Completed NCT00994682 Phase 4
21 Role of Pioglitazone in the Treatment of Non-alcoholic Steatohepatitis (NASH) Completed NCT00227110 Phase 4
22 Orlistat (Xenical) in the Treatment of Overweight Patients With Nonalcoholic Steatohepatitis (NASH) Completed NCT00160407 Phase 4
23 Antidiabetic Effects on Intrahepatic Fat Completed NCT03068065 Phase 4
24 The Effect of Vitamin D Supplementation in Type 2 Diabetes Completed NCT01854463 Phase 4
25 A 24 Week, Multicenter, Prospective, Open-labeled, Single-arm, Exploratory Phase 4 Clinical Trial to Evaluate the Safety and Efficacy of Lobeglitazone in Decreasing Intrahepatic Fat Contents in Type 2 Diabetes With NAFLD Completed NCT02285205 Phase 4
26 Liver Safety Under Upfront Arimidex vs Tamoxifen Completed NCT00537771 Phase 4
27 Effect of a Basal/Pre-Meal Insulin Strategy (Detemir/Aspart) on Insulin Secretion and Action in Type 2 Diabetes Completed NCT00998335 Phase 4
28 MRI Substudy; Metabolic Changes Due to Iatrogenic Hypogonadism Completed NCT02102646 Phase 4
29 Effect of Liraglutide on Cardiovascular Endpoints in Diabetes Mellitus Type 2 Patients Completed NCT01761318 Phase 4
30 Pioglitazone in Hepatitis C Completed NCT00189163 Phase 4
31 Use of Metformin in Treatment of Childhood Obesity Completed NCT02274948 Phase 4
32 Mechanism of Fatty Acid-induced Impairment of Glucose-simulated Insulin Secretion - Effect of Buphenyl Completed NCT00533559 Phase 4
33 Weight Loss Improves Renal Hemodynamics Completed NCT01356394 Phase 4
34 Lactate Metabolism Study in HIV Infected Persons Completed NCT00202228 Phase 4
35 A Study of the Effects of Exercise Intensity on Insulin Sensitivity in Overweight Youth Completed NCT00755547 Phase 4
36 Anti-fatigue Effect of Korean Red Ginseng in Patients With Non-alcoholic Hepatitis Completed NCT02331589 Phase 4
37 Adding Liraglutide to High Dose Insulin: Breaking the Cycle Completed NCT01505673 Phase 4
38 Omega-3 Fatty Acid-Based Parenteral Nutrition Improves Postoperative Recovery for Cirrhotic Patients With Liver Cancer Completed NCT02321202 Phase 4
39 Latino Study - A Study of PEGASYS (Peginterferon Alfa-2a (40KD)) and COPEGUS (Ribavirin) in Treatment-Naive Patients With Chronic Hepatitis C-Genotype 1. Completed NCT00107653 Phase 4
40 Safety and Tolerance on Lipids of Parenteral and Enteral Nutrition in Critically Ill Patients With Liver Failure Completed NCT00522730 Phase 4
41 Effect Of Exenatide Treatment on Liver Fat Content in Patients With Diabetes Completed NCT01432405 Phase 4
42 Effects of Metformin on Hepatic FFA Metabolism Completed NCT01729156 Phase 4
43 Effect of Exenatide on Liver and Heart Fat and Inflammation Completed NCT01951651 Phase 4
44 Acute Regulation of Intestinal and Hepatic Lipoprotein Production by Glucagon Completed NCT01155206 Phase 4
45 Effect of Pioglitazone and Exenatide on Body Weight and Beta Cell Function Completed NCT00845182 Phase 4
46 A Study of the Safety and Efficacy of Fabrazyme (Agalsidase Beta) as Compared to Placebo in Patients With Advanced Fabry Disease Completed NCT00074984 Phase 4
47 A Study of the Safety and Efficacy of Fabrazyme in Patients With Fabry Disease Completed NCT00081497 Phase 4
48 Switch From Combivir or Trizivir to Truvada - Mitochondrial Effects Completed NCT00960622 Phase 4
49 Influence of an Oral Nutritional Supplement Rich in Omega-3 Fatty Acids on Functional State and Quality of Life in Malnourished Patients With Gastroenterological Tumors Completed NCT00168987 Phase 4
50 Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients Completed NCT01098760 Phase 4

Search NIH Clinical Center for Nonalcoholic Steatohepatitis

Genetic Tests for Nonalcoholic Steatohepatitis

Anatomical Context for Nonalcoholic Steatohepatitis

MalaCards organs/tissues related to Nonalcoholic Steatohepatitis:

39
Liver, Kidney, Testes, Ovary, T Cells, Neutrophil, Small Intestine

Publications for Nonalcoholic Steatohepatitis

Articles related to Nonalcoholic Steatohepatitis:

(show top 50) (show all 761)
id Title Authors Year
1
Treating Nonalcoholic Steatohepatitis (NASH) in Children: Not a Cinch Task. ( 28073147 )
2017
2
Hepatic vagus nerve regulates Kupffer cell activation via I+7 nicotinic acetylcholine receptor in nonalcoholic steatohepatitis. ( 28044208 )
2017
3
Iron Overload in the Liver of 2 Children: Nonalcoholic Steatohepatitis and Juvenile Hemochromatosis. ( 28067690 )
2017
4
Caspase 3, 6, 8, and 9 Gene Expression in Peripheral Blood Leukocytes and Plasma Concentrations of IL-6 and TNF-I+ in Carriers of Different Polymorphic Marker -174G>C Genotypes of IL6 Gene Associated with the Risk of Nonalcoholic Steatohepatitis. ( 28091912 )
2017
5
A Differences in hepatic expression of iron, inflammation and stress-related genes in patients with nonalcoholic steatohepatitis. ( 28051796 )
2017
6
Pathological findings of nonalcoholic steatohepatitis and nonalcoholic fatty liver disease. ( 27995687 )
2017
7
Stage of fibrosis and portal pressure correlation in nonalcoholic steatohepatitis. ( 28079667 )
2017
8
Global Deletion of Glutathione S-Transferase A4 Exacerbates Developmental Nonalcoholic Steatohepatitis. ( 27998724 )
2017
9
Association of noninvasive quantitative decline in liver fat content on MRI with histologic response in nonalcoholic steatohepatitis. ( 27582882 )
2016
10
Devilish Effects of Taz in Nonalcoholic Steatohepatitis. ( 28068221 )
2016
11
Nonalcoholic Steatohepatitis and Hepatocellular Carcinoma: Brazilian Survey. ( 27626470 )
2016
12
Adiponectin as a target for the treatment of nonalcoholic steatohepatitis with thiazolidinediones: A systematic review. ( 27506737 )
2016
13
Emerging and future therapies for nonalcoholic steatohepatitis in adults. ( 27564402 )
2016
14
Role of Uric Acid Metabolism-Related Inflammation in the Pathogenesis of Metabolic Syndrome Components Such as Atherosclerosis and Nonalcoholic Steatohepatitis. ( 28070145 )
2016
15
A Nonalcoholic steatohepatitis in morbid obese patients: coffee consumption vs. disease severity. ( 27049488 )
2016
16
Impact of physical activity on nonalcoholic steatohepatitis in people with nonalcoholic simple fatty liver: A prospective cohort study. ( 27143495 )
2016
17
Acidophil bodies in nonalcoholic steatohepatitis. ( 26980020 )
2016
18
The Metabolic Syndrome and Its Influence on Nonalcoholic Steatohepatitis. ( 27063266 )
2016
19
Hepatocyte TAZ/WWTR1 Promotes Inflammation and Fibrosis in Nonalcoholic Steatohepatitis. ( 28068223 )
2016
20
Screening Strategies for Nonalcoholic Steatohepatitis in High-Risk Individuals: Trimming Away the Fat. ( 27010545 )
2016
21
Nonalcoholic Steatohepatitis Modulates Membrane Protein Retrieval and Insertion Processes. ( 27604106 )
2016
22
Discovering a critical transition state from nonalcoholic hepatosteatosis to nonalcoholic steatohepatitis by lipidomics and dynamical network biomarkers. ( 26993042 )
2016
23
Hyperthyroidism Improves the Pathological Condition of Nonalcoholic Steatohepatitis: A Case of Nonalcoholic Steatohepatitis with Graves' Disease. ( 27477408 )
2016
24
Interactions of a PPARGC1A Variant and a PNPLA3 Variant Affect Nonalcoholic Steatohepatitis in Severely Obese Taiwanese Patients. ( 27015186 )
2016
25
Elafibranor, an Agonist of the Peroxisome Proliferator-Activated Receptor-I+ andA -I', Induces Resolution of Nonalcoholic Steatohepatitis Without Fibrosis Worsening. ( 26874076 )
2016
26
Nonalcoholic steatohepatitis heralding olmesartan-induced sprue-like enteropathy. ( 27486047 )
2016
27
Mainstream cigarette smoke accelerates the progression of nonalcoholic steatohepatitis by modulating Kupffer cell-mediated hepatocellular apoptosis in adolescent mice. ( 27180087 )
2016
28
Electronegative LDL is linked to high-fat, high-cholesterol diet-induced nonalcoholic steatohepatitis in hamsters. ( 27012620 )
2016
29
Ezetimibe, an NPC1L1 inhibitor, is a potent Nrf2 activator that protects mice from diet-induced nonalcoholic steatohepatitis. ( 27634173 )
2016
30
Resveratrol and fenofibrate ameliorate fructose-induced nonalcoholic steatohepatitis by modulation of genes expression. ( 26973390 )
2016
31
Targeting the Mitochondrial Pyruvate Carrier Attenuates Fibrosis in a Mouse Model of Nonalcoholic Steatohepatitis. ( 28027586 )
2016
32
Structure of proof of concept studies that precede a nonalcoholic steatohepatitis development program. ( 28032901 )
2016
33
Nonalcoholic Steatohepatitis and Endpoints in Clinical Trials. ( 28035202 )
2016
34
Mitochondrial DNA from hepatocytes as a ligand for TLR9: Drivers of nonalcoholic steatohepatitis? ( 27610009 )
2016
35
Nonalcoholic Steatohepatitis is associated with a state of betaine-insufficiency. ( 27614103 )
2016
36
Hypolactasia is associated with insulin resistance in nonalcoholic steatohepatitis. ( 27648154 )
2016
37
Histology of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis in Adults and Children. ( 27063270 )
2016
38
Green tea extract treatment reduces NFI_B activation in mice with diet-induced nonalcoholic steatohepatitis by lowering TNFR1 and TLR4 expression and ligand availability. ( 28038359 )
2016
39
Treatment with Oxidized Phospholipids Directly Inhibits Nonalcoholic Steatohepatitis and Liver Fibrosis Without Affecting Steatosis. ( 27074921 )
2016
40
New Pharmacologic Agents That Target Inflammation and Fibrosis in Nonalcoholic Steatohepatitis-Related Kidney Disease. ( 27521506 )
2016
41
Upregulation of autophagy components in alcoholic hepatitis and nonalcoholic steatohepatitis. ( 27432584 )
2016
42
Serotonin Syndrome Resulting From Acute Decompensation of Nonalcoholic Steatohepatitis Cirrhosis in a Patient Chronically Treated With Citalopram and Tramadol. ( 27838198 )
2016
43
The role of extended criteria donors in liver transplantation for nonalcoholic steatohepatitis. ( 27554622 )
2016
44
Derivation and validation of a scoring system for predicting nonalcoholic steatohepatitis in Taiwanese patients with severe obesity. ( 28089433 )
2016
45
Drug-induced Nonalcoholic Steatohepatitis. ( 27040342 )
2016
46
Shugan Xiaozhi Decoction Attenuates Nonalcoholic Steatohepatitis by Enhancing PPARI+ and L-FABP Expressions in High-Fat-Fed Rats. ( 28003852 )
2016
47
Hepatic and serum lipid signatures specific to nonalcoholic steatohepatitis in murine models. ( 27510159 )
2016
48
Extract of a polyherbal formulation ameliorates experimental nonalcoholic steatohepatitis. ( 27114939 )
2016
49
Promising therapies for treatment of nonalcoholic steatohepatitis. ( 27501374 )
2016
50
Heat Shock Protein 27 is down-regulated in Ballooned Hepatocytes of Patients with Nonalcoholic Steatohepatitis (NASH). ( 26935030 )
2016

Variations for Nonalcoholic Steatohepatitis

Expression for Nonalcoholic Steatohepatitis

Search GEO for disease gene expression data for Nonalcoholic Steatohepatitis.

Pathways for Nonalcoholic Steatohepatitis

GO Terms for Nonalcoholic Steatohepatitis

Cellular components related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 extracellular space GO:0005615 9.1 ADIPOQ GPT HFE INS LEP RETN

Biological processes related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

(show all 17)
id Name GO ID Score Top Affiliating Genes
1 response to hypoxia GO:0001666 9.71 ADIPOQ LEP PPARA
2 response to ethanol GO:0045471 9.69 ADIPOQ CYP2E1 LEP
3 glucose homeostasis GO:0042593 9.65 ADIPOQ INS LEP
4 circadian rhythm GO:0007623 9.58 ADIPOQ LEP MTTP
5 acute-phase response GO:0006953 9.57 HFE INS
6 negative regulation of blood pressure GO:0045776 9.56 ADIPOQ PPARA
7 positive regulation of glucose import GO:0046326 9.55 ADIPOQ INS
8 positive regulation of cellular protein metabolic process GO:0032270 9.52 ADIPOQ INS
9 negative regulation of gluconeogenesis GO:0045721 9.49 ADIPOQ INS
10 negative regulation of macrophage derived foam cell differentiation GO:0010745 9.46 ADIPOQ PPARA
11 positive regulation of insulin receptor signaling pathway GO:0046628 9.43 INS LEP
12 response to insulin GO:0032868 9.43 LEP PPARA RETN
13 positive regulation of peptide hormone secretion GO:0090277 9.37 HFE INS
14 glucose metabolic process GO:0006006 9.33 ADIPOQ INS LEP
15 negative regulation of appetite GO:0032099 9.32 LEP PPARA
16 negative regulation of receptor binding GO:1900121 8.96 ADIPOQ HFE
17 negative regulation of feeding behavior GO:2000252 8.62 INS RETN

Molecular functions related to Nonalcoholic Steatohepatitis according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 hormone activity GO:0005179 8.92 ADIPOQ INS LEP RETN

Sources for Nonalcoholic Steatohepatitis

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....